LAC countries participation: ERAPerMed call 2020
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
LAC countries participation: ERAPerMed call 2020 Mauricio García-Franco, Coordination Unit GA-ID: 779282 National Health School, National Institute of Health Carlos III (ISCIII), Madrid, 07th-08th November 2019 EULAC-PerMed Summer School Personalised Medicine Research in the Health System
ERA PerMed – ERA NET on Personalised Medicine Time frame: 1 December 2017 – 30 November 2022 Consortium: 32 funding organisations from 23 countries (AT, BE, CA, DE, DK, ES, EE, FI, FR, HR, HU, IE, IL, IT, LV, LU, NL, NO, PL, RO, SE, SI, TR) The biggest ERA Net in health 19 EU countries 3 associated countries (H2020) : IL, NO, TR 1 third country: CA 23 countries 5 regions 32 partners ES (Navarre, Catalane) IT (Lombardy) DE (Saxony) Coordination: CA (Québec) Instituto de Salud Carlos III (ISCIII), SPAIN Joint Transnational Calls (JTCs) 1 Call cofunded by the EC 2018 3 Calls non-cofunded : 2019, 2020, 2021
ERA PerMed – ERA NET on Personalised Medicine Time frame: 1 December 2017 – 30 November 2022 Consortium: 32 funding organisations from 23 countries (AT, BE, CA, DE, DK, ES, EE, FI, FR, HR, HU, IE, IL, IT, LV, LU, NL, NO, PL, RO, SE, SI, TR) The biggest ERA Net in health 19 EU countries 3 associated countries (H2020) : IL, NO, TR 1 third country: CA ERA PerMed and ICPerMed are closely connected. 23 countries 5 regions ICPerMed Action Plan and SRIA are 32 partners ES (Navarre, Catalane) consulted during the preparation of IT (Lombardy) the calls DE (Saxony) Coordination: CA (Québec) https://www. Instituto de Salud Carlos III icpermed.eu/ (ISCIII), SPAIN Joint Transnational Calls (JTCs) www.erapermed.eu 1 Call cofunded by the EC 2018 3 Calls non-cofunded : 2019, 2020, 2021 (decision to go adopted on 12/09/2019) Source: ERA PerMed ANR, France
ERAPerMed Definition of Personalised Medicine: Stated in the Strategic Research and Innovation Agenda (SRIA) of PerMed, adopted from the H2020 advisory group*: • “Personalised Medicine refers to a medical model using characterisation of individuals’ phenotypes and genotypes (e.g. molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention.” * European Commission. Advice for 2016/2017 of the Horizon 2020 Advisory Group for Social Challenge 1, “Health, Demographic Change and Wellbeing
ERAPerMed – Structure WP1 - COORDINATION & MANAGEMENT EC cofunded call WP6 - ADDITIONAL WP2+WP3+WP4+WP5 NON COFUNDED CALLS WP 7 - STRATEGIC SUPPORT ACTIVITIES
ERAPerMed – Structure EC cofunded call WP 2 - PREPARATION AND LAUNCH OF THE EU CO-FUNDED CALL WP 3 – EVALUATION & PROPOSAL SELECTION OF THE EU CO-FUNDED CALL WP 4 - FOLLOW UP AND MONITORING OF THE EU CO- FUNDED PROJECTS WP 5 - COMMUNICATION AND EXPLOITATION OF RESULTS OF THE EU CO-FUNDED CALL
ERAPerMed – Content About ERA PerMed JTC 2018 JTC 2019 JTC 2020 Steps of a Call
ERAPerMed – EU co-funded JTC 2018 19 EU countries 3 associated countries (to Horizon 2020): Turkey, Norway, Israel 1 third country: Canada 31 Partners 23 Countries 5 regions Joint Call Secretariat (JCS) Countries´ ex ante Budget Instituto de Salud Carlos III (ISCIII) 27 M € (Aprox.) SPAIN Two step procedure Launch: 14th February 2018 Timeline: Submission deadline for Pre-proposals: 10th April 2018 Submission deadline for invited Full-proposals: 26th JuLY 2018
ERAPerMed – EU co-funded JTC 2018 Scope of the call TOPIC: RESEARCH PROJECTS ON PERSONALISED MEDICINE – SMART COMBINATION OF PRE-CLINICAL AND CLINICAL RESEARCH WITH DATA AND ICT SOLUTIONS
ERAPerMed – EU co-funded JTC 2018 Facts and Figures • Pre-proposal stage: • 159/143 submitted projects • 741 partners requesting to 30 funding organisations • 176.21 M € requested funding • 50 Pre-proposals invited to submit a Full proposal • 75 evaluators from institutions affiliated to 24 countries (25% females) • Full proposal stage: • 50 submitted projects • 25 Proposals funded, 131 partners requesting to 21 funding organisations. • 28.27 M € requested funding • 23 evaluators from institutions affiliated to 15 countries
ERAPerMed – Content About ERA PerMed JTC 2018 JTC 2019 JTC 2020 Steps of a Call
ERAPerMed – non EU co-funded JTC 2019 17 EU countries 3 associated countries (to Horizon 2020): Turkey, Norway, Israel 2 third countries: Canada and Egypt 6 regions (Saxony, Quebec, Lombardy, 30 Partners 22 Countries Navarra ,Cataluña and Tuscany 1 charity: AECC Call Secretariat (JCS) Agence National de la Recherche (ANR) Countries´ ex ante Budget FRANCE 31.42 M € Two step procedure Launch: 9th January 2019 Submission deadline for Pre-proposals: 7th March 2019 Timeline: Submission deadline for invited Full-proposals: 17th June 2019 2020-Q1: Expected start of granted projects.
ERAPerMed – non EU co-funded JTC 2019 Scope of the call TOPIC: PERSONALIZED MEDICINE: MULTIDISCIPLINARY RESEARCH TOWARDS IMPLEMENTATION Each consortium submitting a proposal must address at least one module of Research Area 3 and at least one module of Research Area 1 or 2 Proposals must be interdisciplinary and clearly demonstrate the potential impact in Personalized Medicine as well as the added value of transnational collaboration
ERAPerMed –non EU co-funded JTC2019 Facts and Figures • Pre-proposal stage: • 196 submitted projects • 906 partners requesting to 30 funding organisations (27 own funding) • 216 M € requested funding • 56 Pre-proposals invited to submit a Full proposal • 102 evaluators from institutions affiliated to 26 countries (33% females) • Full proposal stage: • 56 submitted projects • 22 Proposals expected to be funded, 108 partners requesting to 24 funding organisations (5 partners on own funding). • 24.6 M € requested funding • 29 evaluators from institutions affiliated to 17 countries
ERAPerMed – Content About ERA PerMed JTC 2018 JTC 2019 JTC 2020 Steps of a Call
ERAPerMed – non EU co-funded JTC 2020 17 EU countries 3 associated countries (to Horizon 2020): Turkey, Norway, Israel 3 third countries: Canada, Egypt, Panama 34 Partners 23 Countries 6 regions (Saxony, Wallonia, Lombardy, Navarra ,Cataluña and Tuscany) Call Secretariat (JCS) 1 charity: AECC German Aerospace Center (DLR) GERMANY Countries´ ex ante Budget 23 M € approx. Two step procedure Launch: December 2019 Timeline: Submission deadline for Pre-proposals: March 2020 Submission deadline for invited Full-proposals: June 2020 PRE-ANNOUNCEMENT JTC 2020 ALREADY ONLINE http://www.erapermed.eu/category/news/
ERAPerMed – non EU co-funded JTC 2020 Scope of the call TOPIC: “PERSONALISED MEDICINE – PRE-/CLINICAL RESEARCH, BIG DATA AND ICT, IMPLEMENTATION AND USER’S PERSPECTIVE” Each project proposal MUST address at least one module of Research Area 3 and at least one module of Research Area 1 or 2.
Partnering Tool https://partnering.pt-dlr.de/ICPerMed
ERAPerMed – Content About ERA PerMed JTC 2018 JTC 2019 JTC 2020 Steps of a Call
• Application done by each given • Proposal by Coordinator participant (coordinator or Reception of Reception de • (received by the Call partner) research group to its Secretariat) Proposals Solicitudes given Regional/national funding organization • Central Eligibility • Selection of evaluators International Nacional/ • National/Regional Eligibility • Remote and face-to-face Phase(s) Regional Phase phace(s) • Committed funds Rules Ranking list Available funds • Possible national/ regional increments Selection of Projects to be funded National/ Steps of an Regional Funding process ERA-NET Call Follow up: • National/Regional • International
International Eligibility (central) Criteria • Each consortium must involve at least 3 partners eligible for funding. (From a participating national/regional FO). • At least 3 different countries. • Maximum two participants per country. • Project coordinator must be eligible to be funded. • The maximum number of partners per project is 6 (7 if underrepresented) • No more than two partners from the same country. • No more than one partner with its own funding is allowed. * Each FO has its own national/regional eligibility criteria
International Eligibility (central) Criteria FURTHER REQUIREMENTS • Type of eligible organisation (variable); Academia or research institutes; Clinical/public health sector; (Industry) Private partners, e.g. SMEs. Patient organisations. (depends upon the given FO) • The proposal must comply with the topic of the call. • Each partner represented by a single (PI). • Comply with the formats required in the application documents/online tool. Full-proposal Number of partners in the Pre-proposal (only by inclusion of one underrepresented country) proposal 3 4 5 6 7 Maximum number of partners 0 1 1 1 1 with own funding Maximum number of partners ERAPerMed 1 2 2 Convocatoria 2 2019 2 per country
Steps for International Submission st 1 Phase (Pre-proposal) • Register in the corresponding online tool (Coordinator)
Steps for International Submission st 1 Phase (Pre-proposal) • Important. Obtain and read all relevant documents: 1. Central: Call Text, Participant's Guidelines, Pre-proposal Form, Templates required by the Secretariat (DMP, Exploratory Clinical Studies). 2. National/regional; e.g. pre-eligibility forms.
Steps for International Submission st 1 Phase (Pre-proposal) • To be submitted only by Coordinator and in English. • Comply with the required formats in each document to be submitted; DIN-A4, Calibri 11, a single space, maximum number of pages per section, in PDF, maximum 8 megabites. • Comply with deadlines, in date and time (the server closes). • Comply with the requirements regional/national funding agency where you are eligible. • Make sure you provide an appropriate contact email.
Steps for International Submission nd 2 Phase (Full Proposal) . • Obtain and read all relevant documents: Full proposal template. • To be submitted only by Coordinator and in English. • Comply required formats. • Comply with online limits in date and time. • Be aware of the rebuttal ("reply period"). Information sent only to the Coordinator's email.
Evaluation Process • 2-stage calls (pre-proposal and full proposal). • Remote and face-to-face peer review evaluation panels. • At least 3 evaluations per project. • Evaluation criteria: Excellence, Impact and Implementation of the project. • Panel between 50 and 90 experts for remote evaluation and between 15 and 25 evaluators for face-to-face evaluation. • Score from 0 to 5 per criterion (Total from 0 to 15 points). • There may be a threshold for criteria and/or a threshold for total score.
Evaluation Process Evaluators are selected by: I. Scientific adequacy (fitting expertise). II. Availability during the phases of the evaluation process. III. Gender balance. IV. Geographical balance. V. No Conflicts of Interest. VI. Preference if previous experience in evaluation panels. • Confidentiality agreement is required.
Evaluation Process A disqualifying Conflict of Interest (CoI) exists if an expert: - was involved in the preparation of the proposal; - stands to benefit directly should the proposal be accepted; - has a close family relationship (relatives until second degree) with any person representing an applicant institution in the proposal; - is a director, trustee or partner of an applicant organisation; - is employed by one of the applicant organisations in a proposal; - is in any other situation that compromises his or her ability to evaluate the proposal impartially. A potential conflict of interest may exist, even in cases not covered by the clear disqualifying conflicts indicated above, if an expert: - was employed by one of the applicant institutions in a proposal within the previous three years; - is involved in a contract or research collaboration (including publications) with an applicant or has been so in the previous three years; - is in any other situation that could cast doubt on his or her ability to evaluate the proposal impartially, or that could reasonably appear to do so in the eyes of an external third party. In the case of a conflict of interest, the Joint Call Secretariat has to be informed immediately so that a substitute can be found. At the PRP meeting, reviewers should not be present when discussing their host institution’s application or other proposals with conflicts of interests. In the case of a conflict of interest, they will be asked to leave the room.
Evaluation steps Reception of Pre- Phase 1 Proposals Pre-Proposal National/ Regional Assignment of Eligibility Central eligibility evaluators Remote evaluation • Preliminary Ranking list • PRP Face-to-Face evaluation 2 to 3 times Rules Ranking list available funds Selection of consortia Coordinators are • CSC Meeting invited to Submit a Full informed Proposal
Evaluation steps Reception of Full Phase 2 Proposals Full Proposal National/ Regional Assignment of Eligibility Central eligibility evaluators Remote evaluation • Evaluators’ reports • Preliminary Ranking list • Optional for participants Rebuttal period • PRP Face-to-Face evaluation • Committed funds Rules Available Final Ranking List • Possible national/ funds regional increments Selection of Projects Coordinators are • CSC Meeting to be Funded informed
Ejemplo de Lista de Prelación SELECTED Luxembour The Rank FOR Germany Austria Belgium France Norway Slovakia Slovenia Spain TOTAL g Netherlands FUNDING 14 YES 597.000 250.000 - - - 435.000 - - - 225.000 1.507.000 14 YES 598.000 - 198.000 498.000 - - - - - - 1.294.000 14 YES 598.000 - - 250.000 283.000 - - - - - 1.131.000 13 YES 384.000 283.000 - - - - 60.000 210.000 150.000 - 1.087.000 13 YES 573.000 - - 409.000 - 219.000 - - - - 1.201.000 12 NO 600.000 - - - 299.000 - 120.000 168.000 - 225.000 1.412.000 12 NO 400.000 237.000 - 246.000 - - - - 100.000 - 983.000 12 NO 600.000 - - 208.000 - 435.000 - - - 225.000 1.468.000 12 NO 600.000 - - - - 650.000 - - - 225.000 1.475.000 11 NO - - 200.000 248.000 - 647.000 - - - - 1.095.000 11 NO - - - 250.000 - - - 210.000 123.000 - 583.000 11 NO 444.000 - - 294.000 300.000 - - - - - 1.038.000 11 NO 245.000 212.000 - - - - - 186.000 - - 643.000 9 NO 600.000 - - - - - - - 100.000 225.000 925.000 9 NO - 250.000 - 534.000 - - - 160.000 - - 944.000 9 NO 600.000 - 120.000 198.000 - - - - - - 918.000 8 NO 399.000 250.000 - 228.000 - - - - - - 877.000 TOTAL REQUESTED 7.238.000 1.482.000 518.000 3.363.000 882.000 2.386.000 180.000 934.000 473.000 1.125.000 18.581.000 FUNDING NATIONAL/REGION 2.000.000 500.000 200.000 1.000.000 300.000 1.200.000 120.000 210.000 500.000 450.000 6.480.000 AL COMMITMENT
PARTICIPATION ADAVANTAGES As Funding Organization (FO): • Strength the international position of the given FO. • Enhance the networking and quality of their research teams. • Reduce health R&D cost by aligning expenses with other countries/regions (avoiding double funding). • Middle and long term run socio-economic impacts by improving national/regional health service and/or new employment lines linked to enhancement of the health sector industry. As Researcher: • Receiving funding for their research. • Strength the networking and international position. • Knowledge/technology transfer. • Helps/ encourage researchers to become entrepreneurs.
Thank you for your attention! Contact: Mauricio Garcia-Franco, PhD mauriciog@isciii.es COORDINATION UNIT EULAC-PerMed Summer School Personalised Medicine Research in the Health System
You can also read